Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-15T02:42:40.217Z Has data issue: false hasContentIssue false

Chapter 29 - Contraception in Women with Lupus Autoimmune Diseases

from Section 2A - Sexual and Reproductive Healthcare: Contraception

Published online by Cambridge University Press:  16 January 2024

By
Parivakkam S. Arunakumari  and
Charlotte Gatenby
Edited by
Johannes Bitzer  and
Tahir A. Mahmood
Johannes Bitzer
Affiliation:
University Women's Hospital, Basel
Tahir A. Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Get access

Summary

Access to safe and effective contraception is a basic human right for all women, including those with lupus autoimmune diseases (LADs) [1]. Lupus autoimmune diseases predominantly affect young to middle-aged women, a patient population more likely to require contraception [2]. They include systemic lupus erythematosus (SLE) and/or anti-phospholipid syndrome (APS).

Type
Chapter
Information
Textbook of Contraception, Sexual and Reproductive Health , pp. 187 - 191
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. WHO model list of essential medications 21st list 2019. Geneva: World Health Organization, 2019, pp. 46–7.Google Scholar
Parks, C, de Souza Espindola Santos, A, Barbhaiya, M, Costenbader, K. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology. 2017;31(3):306–20.CrossRefGoogle ScholarPubMed
Culwell, K, Curtis, K. Contraception for women with systemic lupus erythematosus. BMJ Sexual and Reproductive Health. 2013;39(1):9–11. https://srh.bmj.com/content/39/1/9.Google ScholarPubMed
Recurrent pregnancy loss. 2nd edition. Strombek-Bever: European Society of Human Reproduction and Embryology, 2017. http://bit.ly/3RuaUxs.Google Scholar
Unlu, O, Zuily, S, Erkan, D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. European Journal of Rheumatology. 2016;3(2):75–84. https://bit.ly/40pvQts.CrossRefGoogle ScholarPubMed
United Kingdom Medical Eligibility Criteria (UK MEC). 2016. http://ukmec.pagelizard.com/2016.Google Scholar
Tesher, M, Whitaker, A, Gilliam, M, Wagner-Weiner, L, Onel, K. Contraception for adolescents with lupus. Pediatric Rheumatology. 2010;8(1):10.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence. Heavy menstrual bleeding: Assessment and management. 2018. https://bit.ly/3JEZ3KP.Google Scholar
Progesterone only pill. 2nd edition. Edinburgh: Clinical Effectiveness Unit, 2015. https://bit.ly/3Y8mVuT.Google Scholar
Progesterone only implants. 1st edition. Edinburgh: Clinical Effectiveness Unit, 2014. http://bit.ly/3l2xNf7.Google Scholar
World Health Organization. Medical Eligibility Criteria for contraceptive use. Geneva: World Health Organization, 2015. https://bit.ly/40wrqRt.Google Scholar
Centers for Disease Control. US Medical Eligibility Criteria (US MEC) for contraceptive use. 2016 | CDC. Cdc.gov. 2020. http://bit.ly/3RhFASx.Google Scholar
Faculty of Sexual and Reproductive Healthcare. FSRH clinical guideline: Emergency contraception (March 2017, amended December 2017). 2017. http://bit.ly/3Y26ZKN.Google Scholar
World Health Organization. Emergency contraception factsheet. 2018. http://bit.ly/3DFpUTh.Google Scholar
Bermas, B, Smith, NA. UpToDate. 2020. http://bit.ly/3DEDmqI.Google Scholar
National Institute for Health and Care Excellence. Cytotoxic drugs | Treatment summary | BNF content published by NICE. 2020. http://bit.ly/3YlspC7.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×